$27.56
+0.06(0.22%)
Mkt Cap $509M
$16.26
$50.96
52-Week Range
At A Glance
1
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.
2
Revenue is primarily driven by Product (68.9%) and Contract Revenues From Collaborations (15.5%).
3
Most recently: . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February (2026-02-03).
$509M
Market Cap
$302M
Revenue
$377M
Net Income
Employees162
Fundamentals
How The Business Makes Money
Revenue by Segment
Product68.9%($481M)
Contract Revenues From Collaborations15.5%($108M)
Royalty Delivery Of Drug Supplies And Others7.3%($51M)
Release Of Share Cost Liability5.7%($40M)
License2%($14M)
Development Milestones0.4%($3M)
Government Contract0.2%($1M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001034842
ISINUS7665597024
CUSIP766559702
Phone650 624 1100
Address1180 Veterans Boulevard, South San Francisco, CA, 94080, US
SEC EDGAR